|
Ä¿¸®¾îÄɾî |
¿Ü±¹°èÁ¦¾à»ç ONCOLOGY PM
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
03.12 |
|
|
Ä¿¸®¾îÄɾî |
´Ù±¹Àû Á¦¾àȸ»ç MSL(Medical Scientific Liaison ):´ë¸®~Â÷
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
2³â¡è |
ä¿ë½Ã |
07.31 |
|
|
Ä¿¸®¾îÄɾî |
±Û·Î¹úÁ¦¾à»ç MSL(»ç¿ø~°úÀå)
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
1³â¡è |
ä¿ë½Ã |
07.22 |
|
|
Ä¿¸®¾îÀλçÀÌÆ® |
´Ü¹éÁú ºÐ¼®±â±â ¿µ¾÷ °æ·ÂÀÚ - Sales Manager
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
»ý¸í°øÇÐ/¹ÙÀÌ¿À ¿µ¾÷ |
2³â¡è |
ä¿ë½Ã |
04.26 |
|
|
Ä¿¸®¾îÄɾî |
´Ù±¹Àû Á¦¾àȸ»ç MSL (oncology /´ë¸®~Â÷Àå±Þ)
¼¿ï ÀüÁö¿ª | ´ëÇпø(¼®»ç) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
1³â¡è |
ä¿ë½Ã |
09.17 |
|
|
ÇãºêÄ¿¸®¾î |
¿Ü±¹°è Cosmetics ±â¾÷ SCM ¹× RA °æ·ÂÀÚ
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Ç°Áú°ü¸®/Ç°Áúº¸Áõ |
2³â¡è |
ä¿ë½Ã |
11.28 |
|
|
Ä¿¸®¾îÄɾî |
´Ù±¹ÀûÁ¦¾àȸ»ç CSO (Clinical Safety Officer)
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
2³â¡è |
ä¿ë½Ã |
09.27 |
|
|
Ä¿¸®¾îÄɾî |
±Û·Î¹ú ÀÇ·áÀåºñ±â¾÷ FDA ÀÎÇã°¡
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
05.10 |
|
|
(ÁÖ)ÇÇ¿¥ÆÄ¿ö |
±¹³»´ë±â¾÷Á¦¾àȸ»ç ÀÓ»óCRA´ë¸®±Þ°æ·ÂÀÚ¸ðÁý
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
04.25 |
|
|
(ÁÖ)KoreaHR |
Major Á¦¾à»ç - (¾à»ç) PV Manager °æ·Â 1³âÀÌ»óÀÚ ¸ðÁý
°æ±â ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
1³â¡è |
ä¿ë½Ã |
11.26 |
|
|
Ä¿¸®¾îÄɾî |
´Ù±¹Àû ¼±µÎÁ¦¾à»ç PV (Pharmacovigilance) Specialist
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
2³â¡è |
ä¿ë½Ã |
02.16 |
|
|
Ä¿¸®¾îÄɾî |
´Ù±¹Àû ¼±µÎÁ¦¾à»ç RA (Regulatory Affairs) Specialist
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
2³â¡è |
ä¿ë½Ã |
02.16 |
|
|
(ÁÖ)ÇÁ¶óÀ̾îƼ |
¿Ü±¹°è À¯¸í Á¦¾à»ç RA(Regulatory Affairs) ´ã´ç
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¾à»ç/ÇѾà»ç |
2³â¡è |
ä¿ë½Ã |
08.10 |
|
|
GNK Inc |
cra, crm °æ·ÂÁ÷ ¸ð½Ê´Ï´Ù.
¼¿ï ÀüÁö¿ª | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.13 |
|
|
¾Æµ¥ÄÚÄÚ¸®¾Æ |
[±Û·Î¹úCRO] ´ë±Ô¸ð CRA °æ·ÂÁ÷ ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
10.25 |
|